Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$76.51 USD
+3.01 (4.10%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $76.74 +0.23 (0.30%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Gilead Sciences, Inc. [GILD]
Reports for Purchase
Showing records 501 - 520 ( 529 total )
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Btripla vs. Atripla and Q2 Earnings Next; Lowering PT to $40.
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Unimpressive Q1:10 Earnings and EASL; Negative Impact of Healthcare Reform among Others; Lowering PT to $47
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
EASL 2010 Preview Part I.Summary of Oral Presentations.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Quad vs. Atripla Hard to Tell from CROI
Provider: WEDBUSH SECURITIES INC.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Presents Detailed Quad Pill and GS 9350 Data - at CROI; Maintain Neutral
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Quad Pill Abstracts for CROI Meeting for Quad Pill Released; Maintain Neutral
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: Merriman Curhan Ford & Co.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Balance Sheet.
Provider: MERRIMAN CURHAN FORD & CO.
Company: Gilead Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Above industry average growth prospects & expected near term pipeline upsides keep growth story intact
Provider: FIRST GLOBAL
Analyst: THOMAS K